AstraZeneca taps PatientsLikeMe's network for drug R&D insights; Reata gets orphan designation;

@FierceBiotech: ICYMI yesterday: After PhIII odyssey, the FDA finally gives Medicines Co a thumbs-up for cangrelor. Report | Follow @FierceBiotech

@JohnCFierce: Roche hustles its PD-L1 'breakthrough' star into 11 late-stage trials. News | Follow @JohnCFierce

> AstraZeneca ($AZN) has signed on to partner with PatientsLikeMe to cull data from its network of some 250,000 patients that will help guide drug development at the pharma giant. AstraZeneca says it plans to use the data reported by patients to "shape future medicine development and help improve outcomes across its main therapeutic areas, with an initial focus on respiratory disease, lupus, diabetes and oncology." The deal comes a year after Genentech signed on to fine-tune its own research activities. Release

> Reata Pharmaceuticals says it won orphan drug designation for bardoxolone as a treatment for pulmonary arterial hypertension. Earlier the same drug failed spectacularly in a study for chronic kidney disease. Release

> The adult stem cell company BioRestorative Therapies has relocated from Jupiter, FL, to Melville, Long Island, New York. Release

Medical Device News

@FierceMedDev: GE VC arm will not be impacted by sale of GE Capital. Updated story | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceDiagnostics: FDA announces LuSys Labs' recall of its unapproved Ebola diagnostic. Story | Follow @VarunSaxena2

@EmilyWFierce: Roche grabs CAPP Medical to gain ground in cancer Dx. FierceDiagnostics article | Follow @EmilyWFierce

> Medtronic-backed spinal imaging startup grabs $9.6M for back pain diagnostic to replace x-ray. Article

> Varian Medical Systems eyes Chinese market with potential Foxconn deal. Article

Pharma News

@FiercePharma: Valeant CEO's 2014 pay pales in comparison to new EVP's $50M-plus. Article | Follow @FiercePharma

@EricPFierce: ICYMI: Here's Baxter release on recall of 8 saline lots, 4 dextrose, 3 Lactated Ringer's Injection. Release | Follow @EricPFierce

> Merck's Frazier joins top-paid pharma CEOs with a $25M package. Report

> Actavis says it'll lose $200M in Namenda sales if appeals court nixes a 'hard switch.' Story

> Currency hurts, Olysio plummets, but J&J pharma growth carries on. Article

Drug Delivery News

> J&J to use drug delivery device for HBV vaccine thanks to $85M partnership. Item

> 'BLAST' laser method allows large particle delivery to 100,000 cells per minute. Article

> KemPharm sets IPO price for up to $56 million. Report

> Israel's Intec discussing $150M drug delivery partnership with Big Pharma company. More

> Developer of surgically delivered microparticles to brain gets $72.5M in latest funding round. News

Pharma Manufacturing News

> Walgreens CEO hints at another supply chain deal. Item

> Actavis asks court to let it stop manufacturing older Alzheimer's treatment. Item

> Vectura will close plant in Germany within the year. Report

> Baxter again having to recall saline solution as shortage persists. Story

> Novo opens $100M plant in Russia. Article

Pharma Asia News

> IDT Australia release on FDA nod for 23 generics begs the question: Where's the beef? Story

> Australia's George Clinical eyes China drug discovery going global. More

> Takeda names U.S. head, bringing first woman to executive team. Report

> India moves partially on bar codes for exported drugs by July. Story

> TVM closes on $50M for China Biopharma plans. Article

Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.